Last reviewed 2026-04-20 · How we verify

Lopinavir and ritonavir

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Diarrhea
• Dysgeusia
• Vomiting
• Nausea
• Hypertriglyceridemia
• Hypercholesterolemia

Serious adverse events

• Pancreatitis
• Hepatomegaly
• Hypersensitivity
• Alanine aminotransferase increased
• Pyrexia
• Rash
• Anemia
• Decreased neutrophil count

Key clinical trials

• A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (PHASE4)
• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
• Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
• Lopinavir/Ritonavir in PLWH With High-Grade AIN (PHASE1)
• Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
• Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Lopinavir and ritonavir CI brief — competitive landscape report
• Lopinavir and ritonavir updates RSS · CI watch RSS
• Centre Hospitalier Universitaire de Saint Etienne portfolio CI